NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP
Tela Bio, Inc. TELA
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$80.3M
▲ 15.8% vs FY2024
EPS · FY25
$-0.83
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-223.4%
Net margin · FY25
-48.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 80.3M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 48 cents on every revenue dollar this year.
Per share
USD -0.83
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-223.4%
Return on equity, FY2025
ROE
Operating margin-42.0%
Net margin-48.4%
Return on assets-46.2%
Each USD of equity lost 223 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+34.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+24.7%
+34.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 81.4M
total assets, end of FY2025
Total assetsUSD 81.4M
EquityUSD 6.3M
CashUSD 50.8M
Gross debtUSD 55.7M
Net debtUSD 4.8M
Current ratio4.20×
Net debt stands at 76% of equity.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
−0.0
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.83
−1.33
−2.04
−2.72
−2.30
−2.23
−17.10
−101.41
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−223.4
−159.9
−281.2
−257.5
−96.3
−72.0
·
·
·
Shares out B
0.04
0.04
0.02
0.02
0.01
0.01
0.01
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed